Any true relief for employer plans remains in the mid-to-distant future–unless pharmaceutical companies decide to proactively reduce prices to fend off reforms. (Photo: Shutterstock)
Employers hoping for quick relief to their prescription drug cost pain were disappointed by President Trump's price-reduction speech Friday. However, the ambitious, multi-pronged attack on escalating prices–dubbed American Patients First– may at least set the stage for further debate. And that could be a positive outcome for benefits plan designers and administrators who now struggle with the unpredictability of plan costs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Dan Cook
Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.
